These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Core Insights - Wave Life Sciences Ltd reported worse-than-expected third-quarter financial results, with losses of 32 cents per share, missing the analyst consensus estimate of 30 cents per share, and quarterly sales of $7.608 million, falling short of the $11.130 million estimate [1] Financial Performance - The company reported quarterly losses of 32 cents per share, which was higher than the expected loss of 30 cents per share [1] - Quarterly sales amounted to $7.608 million, missing the analyst consensus estimate of $11.130 million [1] Clinical Developments - The company achieved key clinical objectives with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, indicating the effectiveness of its proprietary chemistry [2] - WVE-007 is positioned to potentially disrupt the obesity treatment landscape, with advantages such as inducing fat loss, preserving muscle, and improving cardiometabolic health, while avoiding the class effects of GLP-1s [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Wave Life Sciences shares gained 3.1%, trading at $7.26 [2] - Wells Fargo analyst Benjamin Burnett maintained an Overweight rating on the stock but lowered the price target from $18 to $16 [5] - Wedbush analyst Yun Zhong maintained an Outperform rating and raised the price target from $18 to $20 [5]